Tartarian aster

Tartarian Aster (Aster tataricus L.f.): A Comprehensive Reference

1. Identity and Botanical Characterization

1.1 Nomenclature and Taxonomy

Aster tataricus, commonly known as Tartarian aster and Tatarinow's aster, is a member of the Aster genus of flowering plants. It is a perennial herb of the genus Aster in the Asteraceae (Compositae) family. Its primary drug name in the pharmacopeial tradition is Radix Asteris, referring to the medicinal root and rhizome; in Chinese medicine it is written 紫菀 (Zǐ Wǎn). It is also known by Chinese regional common names such as Huan Hun Cao (还魂草), Qing Wan (青菀), and Shan Ma Lan (山马兰). In Japanese the plant is called Shion (紫苑), a term etymologically composed of "purple" (紫, shi) and "garden/herbaceous plant" (苑, on), evoking imagery of a lush, violet-hued natural setting.

The scientific name Aster tataricus provides clues about its geographical origins. The genus name Aster is derived from the Greek word for "star," referencing the star-like appearance of its blooms, while the species epithet tataricus refers to the Tatar people of Asia, highlighting the regions where the plant is commonly found.

1.2 Botanical Description and Natural Distribution

The plant is a perennial that typically grows up to 2 meters tall and spreads up to 1.2 meters wide. The stem is described as scabrous, with few narrower leaves. Radical leaves are lanceolate-ovate, deeply serrated with the exception of the apex and base of the leaf, and often decurrent into petioles. Flower count ranges from five to eight in a single inflorescence, each large in proportion. Each plant produces a profusion of small, star-shaped blooms that can be blue, lavender, or violet, often with a yellow center.

Aster tataricus is a perennial herbaceous plant belonging to the family Asteraceae and native to East Asia, including regions of China, Japan, Korea, and Siberia. The plant is distributed across China, Korea, Japan, the northern United States, and eastern Siberia in Russia. It thrives in shady, humid areas at altitudes of 400–2,000 m.

1.3 Medicinal Parts and Common Preparations

Radix Asteris (RA), also known as 'Zi Wan', is the dried root and rhizome of Aster tataricus L.f., which has been used to treat cough and asthma in many countries such as China, Japan, Korea, and Vietnam. The medicinal parts of A. tataricus are flowers, leaves, roots, and rhizomes, though the root and rhizome are by far the most widely used official drug form.

Roots were excavated in spring and autumn, and braided and dried in the sun, or directly dried after removal of the knotted rhizomes (commonly known as "mother roots") and sediment. The product is called "Sheng Zi Wan" when directly dried and "Mi Zi Wan" when processed with refined honey. In some Asian countries, young seedlings, tender stems, and leaves harvested from May to June are consumed as vegetables. Additionally, A. tataricus is used in the production of essential oils, pesticides, antioxidants in edible oils, and other products.

The plant is commonly used in traditional Chinese medicine; the root is known as Zi Wan or Radix Asteris Tatarici. The plant is also cultivated, mainly in Korea for medicinal use, and is sometimes grown as an ornamental in gardens. In temperate regions of America, Europe, and northern Asia, A. tataricus is an important cash crop with high ornamental value, and its ability to attract bees and butterflies makes it a popular flower in Europe and America.

2. Traditional and Historical Use

2.1 Earliest Records and Classical Chinese Medicine

Aster tataricus L.f. is an extensively used herb in traditional Chinese medicine for more than 2,000 years, where it is known as "Zi wan" or "Fan huncao." The earliest application of A. tataricus can be traced back to the Shennong Materia Medica. It was first recorded in the ancient medical work Shen Nong Ben Cao Jing (Han Dynasty), and subsequently written about in many ancient herbal works, such as the Wu Pu Materia Medica (Wei Jin, 420–589 AD), the Ben Cao Jing Shu (Ming, 1625 AD), and the Ben Cao Feng Yuan (Qing, 1695 AD), for its multiple effects of "warming" the lungs, relieving coughs, eliminating phlegm, and lowering qi.

Aster tataricus was first recorded in Shuo Wen under the alias "Zi Wan" (茈菀). Traditionally, it was utilized to clear lung qi, promote fluid flow, calm adverse-rising energy, relieve cough, resolve sputum, and regulate secretions. It is regarded as an important medicine for lung disease, as it moistens the lungs and relieves cough and phlegm.

It is one of the 50 fundamental herbs of traditional Chinese medicine, where it has the name Zǐwǎn (紫菀). It is associated with a spicy, bitter, and warm nature and belongs to the Lung Meridian in TCM classification.

2.2 Use Across Cultures and Time Periods

This perennial terrestrial herb has been utilized for over 2,000 years in traditional Chinese medicine to treat throat infections, pneumonia, snake bites, tonsillitis, and bronchial infections. The plant was used in treating asthma, tuberculosis, and bronchitis-related disease to relieve the cough.

In most cases, Radix Asteris was used in combination with other traditional Chinese medicines to form prescriptions for the treatment of wind-cold coughs, asthma, consumptive coughs, vomiting, puss formation, and bleeding. Classical multi-herb prescriptions documented across Chinese dynasties included Radix Asteris paired with herbs such as Ephedra sinica, Tussilago farfara, Pinellia ternata, and others, typically as oral decoctions. In 1963, Radix Asteris was included in the Pharmacopoeia of the People's Republic of China, formalizing its status in modern Chinese pharmaceutical regulation.

Traditional prescriptions documented in Chinese dynastic texts report a typical dose range of approximately 2.5–15 g, described in dynastic records as pungent and non-toxic or bitter in taste and flat in nature.

3. Key Chemical Constituents and Active Compounds

3.1 Overall Phytochemical Profile

To date, more than 200 metabolites have been isolated and characterized from A. tataricus, including terpenoids, flavonoids, polypeptides, and others. More precisely, approximately 200 chemical compounds, including 73 terpenes, 34 flavonoids, 26 organic acids, 21 peptides, and 32 other compounds, have been isolated and identified from Aster tataricus, with terpenes being the main active components.

The plant has yielded a diverse array of bioactive compounds, encompassing various chemical classes such as terpenoids, amides, saponins, flavonoids, lignans, and sterols. Modern pharmacological research has revealed that Aster contains a diverse array of bioactive compounds, including terpenoids, flavonoids, peptides, sterols, anthraquinones, phenylpropanoids, and coumarins.

3.2 Terpenoids

Terpenoids are the most abundant and pharmacologically significant class of compounds in Radix Asteris. The signature constituent is shionone, a triterpenoid ketone that is unique to this species and serves as its primary quality marker. Modern studies have revealed that it contains more than 200 kinds of natural metabolites, among which triterpenoids (such as the iconic component shionone), flavonoids, and cyclic peptides play anti-inflammatory, antioxidant, and anti-tumor effects through multi-target synergies. The Chinese Pharmacopoeia (ChP) has designated shionone as a quality marker due to its role as a core anti-inflammatory component in A. tataricus, and the underlying mechanism has been extensively elucidated.

Additional triterpene-class compounds isolated from A. tataricus include epifriedelinol, astertarone A, epishionol, friedelin, psi-taraxasterol, and multiple aster saponins. A series of echinocystic acid glucuronide saponins designated aster saponins Ha, Hb, Hc, Hd, and foetidissimoside A, as well as oleanane-type triterpene glycosides designated aster saponins E, F, and G, have also been documented. Modern pharmacological studies have shown that the triterpenoid shionone in A. tataricus has a significant expectorant and antitussive effect, and it is the feature component of A. tataricus.

The expectoration-inducing effects of Aster tataricus can be attributed to asterone and epimedanol, which have been isolated from petroleum ether and ethyl acetate extracts.

3.3 Flavonoids

Several important flavonoids have been isolated from Aster tataricus, including quercetin, kaempferol, and luteolin, among others. Luteolin and quercetin have been identified as expectorant and antitussive ingredients within the plant. Quercetin and kaempferol were most potent in inhibiting hemolysis, lipid peroxidation, and superoxide radical generation in antioxidant studies. Kaempferol and quercetin have also shown significant effects on inhibiting hemolysis, lipid peroxide reactivity, and immunomodulatory processes.

3.4 Cyclic Peptides (Astins)

Astins (including astin B) are a class of halogenated cyclic pentapeptides isolated from the medicinal herb of Aster tataricus. This family of peptides — designated astins A, B, C, and J, among others — has been the subject of considerable pharmacological research for both anticancer and immunological effects.

The cyclopeptide astin C, isolated from the endophytic fungus Cyanodermella asteris derived from Aster tataricus, has been reported to have potent anti-cancer and immunosuppressive activities. It functions by binding to STING, a crucial cytosolic DNA sensor protein involved in innate immunity. Astin C can suppress the immune system by inducing T-cell apoptosis.

Cyclopeptides exhibit "double-edged sword" properties, demonstrating significant anticancer effects; however, they share structural similarities with cyclochloroside, a hepatotoxic metabolite of penicillin, which can cause liver damage.

3.5 Organic Acids and Other Phenolics

Other phenolic compounds isolated from Aster tataricus roots include scopoletin, emodin, aurantiamide acetate, and 1,7-dihydroxy-6-methyl-anthraquinone. Caffeoylquinic acids and epifriedelinol possess strong anti-oxidant, anti-inflammatory, and anti-cancer activities. Scopoletin can effectively treat diabetes and alleviate inflammation and oxidative stress. Ferulic acid is another organic acid identified as an active constituent and used as an analytical marker in chromatographic quality-control methods.

4. Pharmacological Mechanisms of Action

4.1 Expectorant and Antitussive Mechanisms

Traditional medicine practitioners believed that the expectorant and antitussive role of A. tataricus is ascribed to the tropism of taste. Different from traditional medicine, modern medical practitioners believe that A. tataricus plays a role by reducing inflammatory factors and relaxing bronchial smooth muscle. The triterpenoid shionone and the flavonoids quercetin and luteolin are the principal compounds implicated in these antitussive and mucokinetic effects, based on experimental studies.

4.2 Anti-inflammatory Mechanisms

Through inhibition of NF-κB activation, aster saponin B significantly reduced nitric oxide (NO) production in LPS-induced RAW264.7 cells and blocked phosphorylation of JNK, ERK, and p38 in the MAPK pathway. Collectively, these processes result in a substantial anti-inflammatory effect and effectively inhibit the production of inflammatory cytokines (PGE-2, IL-6, and IL-1β).

Astin C inhibits cGAS–STING signaling and the innate inflammatory response triggered by cytoplasmic DNA. The compound 4-hydroxyphenylacetic acid (4-HPA) in A. tataricus inhibits hyperosmotic and hypoxia-induced HIF-1α in NR8383 macrophages and reduces inflammatory cytokine levels.

4.3 Antioxidant Mechanisms

Compounds isolated from A. tataricus have been compared with regard to their ability to inhibit hemolysis of rat erythrocytes, lipid peroxidation using the FeSO₄–ascorbic acid system, and generation of superoxide radicals using a phenazine methosulfate–nicotinamide adenine dinucleotide system. The flavonoids quercetin and kaempferol emerged as the most potent antioxidant constituents across these assay systems. Terpenes, the main chemical constituents of Aster tataricus, can induce apoptosis and DNA mutations in tumor cells, thereby exerting anti-tumor effects. Caffeoylquinic acids and epifriedelinol possess strong anti-oxidant, anti-inflammatory, and anti-cancer activities.

4.4 Antiviral Mechanisms

An effective dose of Aster tataricus extract (ATE) significantly inhibited influenza A virus (PR8), Newcastle disease virus (NDV), and herpes simplex virus (HSV) replication in RAW264.7 cells. Mechanistically, ATE induced an antiviral state, which includes upregulation of type-I interferon signaling and secretion of IFNs and pro-inflammatory cytokines. In vivo, ATE treatment showed increased survival due to reduced viral titers and less severe pathological changes in the lung, and the observed prophylactic effects were associated with increased secretion of IL-6, IFN-γ, and IFN-β in bronchoalveolar lavage fluid.

Terpenoids in A. tataricus also have certain antiviral activity, especially against HBV. Astataricusones B exerts potent antiviral effects through dual mechanisms: primarily by suppressing the secretion of hepatitis B virus surface antigens (HBsAg and HBeAg) and subsequently inhibiting viral DNA replication.

5. Scientific Evidence by Health Area

5.1 Respiratory System: Cough, Asthma, and Expectorant Activity

The best-established pharmacological domain of Aster tataricus relates to the respiratory system, consistent with more than two millennia of empirical use. Aster tataricus has been used in TCM for the treatment of respiratory diseases for more than 2,000 years. Bioactive compounds confer a wide range of pharmacological activities, including expectorant, cough-suppressing, asthma-relieving, and antimicrobial effects.

Most evidence in this area is derived from animal models and cell-based studies. An in vivo study cited in the 2015 Journal of Ethnopharmacology series investigated the expectorant, antitussive, and anti-inflammatory activities of Aster tataricus extracts and confirmed these activities through pharmacological experiments. The mechanistic basis includes relaxation of bronchial smooth muscle and suppression of inflammatory mediators. One study reported that Aster tataricus attenuates asthma efficiently by simultaneously inhibiting tracheal ring contraction and inflammation.

Evidence strength: Predominantly preclinical (animal and cell-based). Human clinical trials on respiratory outcomes are not reported in the accessible peer-reviewed literature. The traditional use is deeply documented, and pharmacological plausibility has been established at the mechanistic level in vitro and in animal models.

5.2 Anti-inflammatory and Acute Lung Injury

Studies found that the Fraction-75 eluted from Radix Asteris extract could significantly protect against LPS-induced acute lung injury (ALI) in mice, including alleviating the severity of lung pathology, attenuating pulmonary edema, and reducing the release of inflammatory cells. GO functional and pathway analysis revealed that the candidate components were associated with biological processes including the inflammatory response, cellular process, chemokine biosynthetic process, and immune system process. ELISA validation indicated that the candidate components in Radix Asteris extract may protect against LPS-induced ALI mainly through inhibiting the release of inflammatory cytokines and promoting the repair of vascular endothelial tissue.

In cell-based research, the ethanolic root extract (20 and 40 mg/mL concentrations) showed a significant (p < 0.01) decrease in production of reactive oxygen species (ROS), nitrite release, and malondialdehyde (MDA) level in LPS-activated C6 cells compared to the negative control group.

Evidence strength: In vitro and rodent model evidence only. No registered human clinical trials are known. The network pharmacology approach used in the ALI study provides a computational rationale but does not substitute for clinical evidence.

5.3 Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is an irreversible and progressive interstitial lung disease for which no definitive cure exists. Although pirfenidone and nintedanib have been approved for IPF treatment, prolonged usage is often associated with adverse gastrointestinal and neurological side effects, creating an urgent demand for highly effective anti-pulmonary fibrosis drugs with reduced toxicity profiles. Research has explored self-assembled vectors derived from Aster tataricus as a potential anti-fibrotic therapeutic approach in mouse models of bleomycin-induced pulmonary fibrosis.

Evidence strength: Early-stage preclinical (animal model). No human data are available; this represents an emerging research direction rather than an established clinical application.

5.4 Anticancer Activity

Terpenes, the main chemical constituents of Aster tataricus, can induce apoptosis and DNA mutations in tumor cells, thereby exerting anti-tumor effects. The cyclic peptide astins — particularly astins A, B, and C — are the most studied compounds for anticancer potential. Astin B has been studied in hepatic, oral squamous cell carcinoma, and other cancer cell lines. Astin C, isolated from the endophytic fungus Cyanodermella asteris derived from Aster tataricus, has been reported to have potent anti-cancer and immunosuppressive activities, functioning by binding to STING, a crucial cytosolic DNA sensor protein involved in innate immunity.

Its dried root and rhizome hold great promise in the treatment of cough, asthma, tumor, and inflammation. A published cell-line study examining activity against SCC-9 human oral squamous carcinoma cells (PubMed ID 28573230) reported anti-cancer activity, though the specific results in the abstract are descriptive only.

Evidence strength: Strictly in vitro and animal model evidence. There are no peer-reviewed human trials. Mechanistic data are promising at a molecular level, particularly regarding astin–STING interactions, but clinical translation has not yet occurred. Future study should focus on clinical evaluation of isolated compounds to justify their traditional uses and the development of therapeutics.

5.5 Antioxidant Activity

It was discovered that A. tataricus extract has a number of bioactivities, including anti-inflammatory, antihemorrhagic, and antioxidant activities. The antioxidant data are derived from standard in vitro assays including lipid peroxidation, superoxide radical generation, and erythrocyte hemolysis inhibition systems. The flavonoids quercetin and kaempferol are consistently identified as the principal antioxidant agents within the extract.

Evidence strength: In vitro biochemical assays only. No human clinical trials on antioxidant endpoints have been published.

5.6 Antidepressant Activity

Studies have shown that Radix Asteris extracts have various pharmacological activities, including anti-depression. Studies have shown that RA extracts contain terpenes, triterpenoid saponins, organic acids, peptides, and flavonoids, and have various pharmacological activities such as anti-inflammatory, anti-tumor, anti-oxidation, and anti-depression. The anti-depressant effects identified in the literature are based on preclinical behavioral models; the specific mechanisms are not yet fully elucidated in published accessible sources.

Evidence strength: Preliminary, based on preclinical models. No human clinical evidence is available. This represents one of the least developed research areas for this plant.

5.7 Antimicrobial Activity

It has an antibacterial action, inhibiting the growth of Staphylococcus aureus, E. coli, Shigella dysenteriae, B. typhi, Pseudomonas, and Vibrio proteus. Quercetin, kaempferol, and ferulic acid were identified as active compounds in the aqueous fraction, and effective doses of each compound exhibited antiviral effects. Findings suggest that the extract and its active compounds act as immunomodulators and may be potential candidates as a source of promising natural antivirals for animals and humans.

Evidence strength: In vitro and some in vivo (animal) data. No human clinical trials on infectious disease endpoints. Antimicrobial activity is well-documented in cell and agar-diffusion systems.

5.8 Bone Health / Osteoporosis

Research found that ethanolic extracts of Aster tataricus regulated osteoclast differentiation and alleviated osteoporosis as well as related metabolic changes after estrogen depletion. These results indicate that Aster tataricus can be used as an alternative treatment strategy for postmenopausal osteoporosis accompanied by metabolic imbalance.

To investigate the effect of aster shionoside A2 on RANKL-induced RAW264.7 cells and Bone Marrow Macrophages, administering aster shionoside A2 significantly reduced the phosphorylation levels of ERK1/2, JNK, and p38 proteins, inhibited osteoclast-related gene activation in reaction to RANKL, and impeded the transcription and translation of NFATC1 and c-fos throughout the osteoclast differentiation phase. Lee et al. studied the mechanism of the ethanol extract of A. tataricus (ATEE) in alleviating osteoporosis and demonstrated that it significantly inhibited the expression of key osteoclast factor NFATc1, induced by RANKL-mediated upregulation of c-Fos and NFATc1 proteins during osteoclast formation. Additionally, ATEE inhibited RANKL expression and RANK-induced osteoclast formation to delay osteoclast differentiation.

Evidence strength: Cell-based (in vitro) and animal model data only. No human trials. Research is mechanistically detailed regarding osteoclast inhibition but has not advanced to clinical evaluation.

5.9 Metabolic and Glycemic Effects

Pharmacological investigations demonstrated that ATE-derived polyphenolic compounds exhibit metabolic regulatory properties, as evidenced by their ability to significantly attenuate body weight gain and modulate blood glucose levels in rodent models. The coumarin scopoletin, one of the isolated compounds, has been implicated in glycemic modulation. Scopoletin can effectively treat diabetes and alleviate inflammation and oxidative stress in preclinical models.

Evidence strength: Animal model evidence only. No human clinical data are available.

5.10 Urinary System

Compounds from A. tataricus demonstrate pharmacological activities including management of urinary system diseases, an indication referenced in modern pharmacological review literature as a recognized area of investigation. A beneficial effect in mitigating urinary retention has been noted in published reviews. Mechanistic studies on this area are limited in the peer-reviewed literature accessible in English.

Evidence strength: Preliminary; referenced in reviews but not backed by detailed published clinical trials in the accessible literature.

5.11 Gut Microbiota / Probiotic Effects

In vitro, A. tataricus extract exerted a growth-promoting effect on Bifidobacterium and an inhibitory effect on Clostridium perfringens. Therefore, A. tataricus may have a probiotic effect on intestinal flora.

Evidence strength: Single in vitro study. No clinical data.

6. Body Systems Associated with Tartarian Aster

• Respiratory system — primary traditional and modern evidence domain; antitussive, expectorant, anti-asthmatic, acute lung injury, pulmonary fibrosis (preclinical).
• Immune system — anti-inflammatory via NF-κB/MAPK, cGAS–STING modulation; antiviral immunomodulation.
• Musculoskeletal system — osteoclast inhibition; anti-osteoporosis in animal models.
• Oncological (preclinical) — apoptosis induction in tumor cells; cyclopeptide interactions with STING pathway.
• Metabolic system — blood glucose modulation in rodent models; antioxidant pathways.
• Urinary system — traditional use and limited modern investigation.
• Central nervous system — antidepressant properties in preclinical behavioral models.
• Gastrointestinal / microbiome — selective probiotic effects on gut flora in vitro.

7. Dosage Forms and Reported Dosages

Radix Asteris is administered in a variety of pharmaceutical and traditional preparations. The principal forms include raw dried root and rhizome (Sheng Zi Wan), honey-processed root (Mi Zi Wan), decoctions, and as a component in multi-herb proprietary formulas. The roots were excavated in spring and autumn and braided and dried in the sun, or directly dried after removal of the knotted rhizomes. The product is called "Sheng Zi Wan" when directly dried and "Mi Zi Wan" when processed with refined honey.

In traditional classical texts, the dose range documented in pharmacopeial records across Chinese dynasties spans approximately 2.5–15 g, used orally as a decoction, typically in combination with other herbs.

In the preclinical toxicology study examining acute and subchronic toxicity, the study showed that Aster tataricus L.f. can produce toxic effects, mainly on the liver; and the LD₅₀ was 15.74 g/kg body weight in mice, with the subchronic toxicity study using a dosage of 0.34 g/kg/day body weight.

In the cell-based inflammation study, the ethanolic root extract was applied at concentrations of 20 and 40 mg/kg (in cell-line and in vivo contexts) in a one-day treatment protocol.

No standardized human clinical dosage has been formally established in published peer-reviewed clinical trials. All dosages reported in experimental research are derived from animal or in vitro contexts and should not be extrapolated to human use without further evidence.

8. Safety Considerations

8.1 Hepatotoxicity

The most significant and well-documented safety concern with Aster tataricus is hepatotoxicity, attributable principally to its cyclic peptide constituents. Previous works showed that the herbal medicine was hepatotoxic in vivo. Toxicity-guided isolation identified the cyclopeptide astin B as a key hepatotoxic agent. Astin B is structurally similar to cyclochlorotine, a well-known hepatotoxic mycotoxin. Astin B was found to have hepatotoxic effects in vitro and in vivo, with hepatic injury primarily mediated by apoptosis in a mitochondria/caspase-dependent manner. Astin B provoked oxidative stress-associated inflammation in hepatocytes as evidenced by increased levels of reactive oxygen species (ROS), reduced contents of intracellular glutathione (GSH), and enhanced phosphorylation of c-Jun N-terminal kinase (JNK).

A refined toxic fraction (Fr-2) from the ethanol extract of Aster tataricus roots was found to cause hepatotoxic effects proven by elevation of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) in mice serum, further confirmed by histopathological examination of liver tissue.

Among tested ethanol concentrations, 90% ethanol extract was found to be the most toxic. Acute toxicity tests were conducted on the water extract, 75% ethanol extract, and 80% ethanol extract of A. tataricus. Most mice exhibited abnormal behaviors post-administration, such as delayed movement, listlessness, and refusal to eat. The LD₅₀ values were 31.61 g/kg (water), 15.74 g/kg BW (75% ethanol), and 19.19 g/kg (80% ethanol) in mice, respectively. For 75% ethanol extract-treated mice, autopsy revealed darkened liver color, blunt margins, and obvious swelling, congestion, spots, and bleeding points.

8.2 Hemolytic Effects

The different polarity extracts of A. tataricus also exhibit some toxicological characteristics: the astin has a similar structure to that of cyclochloridine, the hepatotoxic metabolite of penicillin; its saponins also have hemolytic effects.

8.3 Structural Analogy to Known Toxins

Cyclopeptides exhibit "double-edged sword" properties, demonstrating significant anticancer effects; however, they share structural similarities with cyclochloroside, a hepatotoxic metabolite of penicillin, which can cause liver damage. Toxicological studies have also explored the mechanisms of liver damage associated with astin.

8.4 Limitations of Current Toxicology Data

There are currently few studies on the toxicology of A. tataricus. Further in-depth research is needed to explore the potential mechanisms underlying the toxicity of A. tataricus. The toxicity of A. tataricus can be reduced through compatibility and processing, but this aspect has received little discussion and further research on quality standardization is needed.

Although its rich chemical constituents have various pharmacological activities, the underlying mechanisms, as well as its toxicity and safety, remain unclear and warrant further investigation.

Aster tataricus has a history of over 2,000 years and is generally considered clinically safe within traditional practice, particularly when used as a water decoction in classical doses and combined with other herbs as formulated in the historical pharmacopeial tradition. The hepatotoxicity risk has been specifically linked to concentrated ethanolic extracts and to specific cyclopeptide fractions, not necessarily to aqueous decoctions at traditional doses.

8.5 Overall Evidence Status and Research Gaps

Aster tataricus is an ancient herbal medicine with a broad spectrum of pharmacological activities that has been used for thousands of years in China, and has shown remarkable effectiveness in the treatment of various diseases, especially cough, asthma, and inflammation. Although its rich chemical constituents have various pharmacological activities, the underlying mechanisms, as well as its toxicity and safety, remain unclear and warrant further investigation.

The evidence base for virtually all pharmacological claims relating to Aster tataricus currently consists of in vitro and animal model data, with no published randomized controlled trials in humans. The traditional use as an expectorant and antitussive in TCM is strongly backed by historical documentation and pharmacological plausibility, but the translation of this into validated clinical evidence has not occurred as of mid-2025. Areas such as anticancer activity, antidepressant effects, and bone health are at early exploratory stages. The hepatotoxic potential of concentrated ethanolic extracts, particularly those rich in cyclic peptides, is a scientifically established concern that warrants attention in any product development or research application.

References

• An updated and comprehensive review of the morphology, ethnomedicinal uses, phytochemistry, and pharmacological activity of Aster tataricus L.f. — PMC / Heliyon (2024)
• Radix Asteris: Traditional Usage, Phytochemistry and Pharmacology of An Important Traditional Chinese Medicine — Molecules (2022), PMC
• Radix Asteris: Traditional Usage, Phytochemistry and Pharmacology of An Important Traditional Chinese Medicine — Molecules (2022), MDPI
• Aster tataricus L.f.: a review on the botany, phytochemistry, ethnopharmacology, pharmacology, toxicology and comprehensive utilization — Frontiers in Pharmacology (2025)
• Aster tataricus L.f.: a review on the botany, phytochemistry, ethnopharmacology, pharmacology, toxicology and comprehensive utilization — PMC (2025)
• Aster tataricus extract and its active compounds display a broad spectrum of antiviral activity in vitro and in vivo — PMC (2025)
• Self-assembled vectors derived from Aster tataricus L.f. mitigate bleomycin-induced pulmonary fibrosis in mice — PMC (2025)
• Network Pharmacology-Based Investigation of Protective Mechanism of Aster tataricus on Lipopolysaccharide-Induced Acute Lung Injury — PMC (2019)
• Effect of Aster tataricus on production of inflammatory mediators in LPS stimulated rat astrocytoma cell line (C6) and THP-1 cells — PMC (2017)
• Antioxidant activity of compounds from the medicinal herb Aster tataricus — Comparative Biochemistry and Physiology (2003), ScienceDirect
• Simultaneous Determination of Five Components in Aster tataricus by Ultra Performance Liquid Chromatography–Tandem Mass Spectrometry — PMC (2016)
• Astin B, a cyclic pentapeptide from Aster tataricus, induces apoptosis and autophagy in human hepatic L-02 cells — PubMed (2014)
• Evaluation of the Acute and Subchronic Toxicity of Aster tataricus L.F. — PubMed (2016)
• Aster tataricus — Wikipedia (botanical reference overview)